My default assumption about most of the PBM reform proposals that have been circulating on Capitol Hill is that they’re smallball: they snack around the edge of the PBM business
Lots of earnings this morning that I haven’t processed yet. Hoping to give those a good look this weekend. Until then … The government formally responded to AstraZeneca’s lawsuit alleging
So I managed to screw up at least two things yesterday. First off, I misspelled Leana Wen’s name. Second, I included the wrong link in discussing Wen’s op-ed. The right
Yesterday was all about Eliquis. First up were the patient listening sessions I keep prattling on about. And while there was some sense that the parade of speakers didn’t shed
I’m on the road this week, which means I had the pleasure of overhearing a woman explaining the concept of a “beer back” to the patron sitting next to her
I don’t think there is a whole lot of analysis needed on the Commonwealth Fund’s look at the impact of high health care costs on consumers. A majority of the
Near-Term Programming Note: Cost Curve is off tomorrow, back Friday for AbbVie earnings and whatever other fun befalls us in the next 48 hours. Long-Term Programming Note: I plan to
The Arc It’s a slow day today, so this is a brief Arc to prematurely flag an interesting trend: we’re a week or into pharma earnings season, and while
Inflection Point Inflection Point is usually for big, driving-the-day kind of news. So a story about the fact that the net price of obesity medicines being a ton lower
Inflection Point If you’re into the IRA, it’s worth carving out a few minutes today to read this white paper from Avalere on the development path of cardiovascular medicines and
